[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100461124":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":36,"locations":45,"responsibleParty":187,"collaborators":190,"id":200,"slug":17,"hasResults":201,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":17,"eligibilityCriteria":205,"healthyVolunteers":201,"sex":206,"minAge":207,"maxAge":17,"enrollmentInfo":208,"targetDuration":17,"studyType":211,"phases":212,"briefSummary":214,"conditions":215,"keywords":217,"overallStatus":48,"whyStopped":17,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":230},{"fullName":5,"class":6},"University Hospital, Linkoeping","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention Arm","EXPERIMENTAL","Drug: Tinzaparin (Innohep®), solution for injection. Administration form: Subcutaneous injection. Dosage: 4500 IU (for subjects weighing below 90 kg) or 8000 IU (for subjects weighing 90 kg and above) daily for 21-28 weeks.",[13],"Drug: Tinzaparin Injectable Solution",{"label":15,"type":16,"description":17,"interventionNames":17},"Control Arm","NO_INTERVENTION",null,[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Tinzaparin Injectable Solution","Subcutaneous injection",[9],[25],"Innohep®",[27,30,32,34],{"name":28,"affiliation":5,"role":29},"Preben Kjölhede, MD, PhD","STUDY_CHAIR",{"name":31,"affiliation":5,"role":29},"Gabriel Lindahl, MD, PhD",{"name":33,"affiliation":5,"role":29},"Anna-Clara Spetz Holm, MD, PhD",{"name":35,"affiliation":5,"role":29},"Anna Karlsson, MD",[37,42],{"name":28,"role":38,"phone":39,"phoneExt":40,"email":41},"CONTACT","+46101030000","3187","preben.kjolhede@regionostergotland.se",{"name":35,"role":38,"phone":39,"phoneExt":43,"email":44},"3117","anna.br.karlsson@regionostergotland.se",[46,71,90,111,130,149,163,180],{"facility":47,"status":48,"city":49,"state":49,"zip":50,"country":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Department of Obstetrics and Gynecology, Highland Hospital","RECRUITING","Eksjö","575 81","Sweden",{"type":53,"coordinates":54},"Point",[55,56],14.97205,57.66643,{"lat":56,"lon":55},[59,63,66,69],{"name":60,"role":38,"phone":61,"phoneExt":17,"email":62},"Christopher Allen, MD","+46102410000","christopher.allen@rjl.se",{"name":64,"role":65,"phone":17,"phoneExt":17,"email":17},"Malena Tiefenthal Thrane, MD","PRINCIPAL_INVESTIGATOR",{"name":67,"role":68,"phone":17,"phoneExt":17,"email":17},"Catarina Notelid Claus, MD","SUB_INVESTIGATOR",{"name":70,"role":68,"phone":17,"phoneExt":17,"email":17},"Hanna Reimerson, MD",{"facility":72,"status":48,"city":73,"state":73,"zip":74,"country":51,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Department of Oncology, Sahlgrenska University Hospital","Gothenburg","41345",{"type":53,"coordinates":76},[77,78],11.96679,57.70716,{"lat":78,"lon":77},[81,85,86,88],{"name":82,"role":38,"phone":83,"phoneExt":17,"email":84},"Karin Bergmark, MD, PhD","+46313421000","Karin.Bergmark@vgregion.se",{"name":82,"role":65,"phone":17,"phoneExt":17,"email":17},{"name":87,"role":68,"phone":17,"phoneExt":17,"email":17},"Pernilla Dahm-Kähler, MD, PhD",{"name":89,"role":68,"phone":17,"phoneExt":17,"email":17},"Boglarka Fekete, MD",{"facility":91,"status":48,"city":92,"state":93,"zip":94,"country":51,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Department of Obstetrics and Gynecology, Ryhov County Hospital","Jönköping","Jönköping County","55305",{"type":53,"coordinates":96},[97,98],14.15618,57.78145,{"lat":98,"lon":97},[101,104,105,107,109],{"name":102,"role":38,"phone":61,"phoneExt":17,"email":103},"Laila Falknäs, MD","laila.falknas@rjl.se",{"name":102,"role":65,"phone":17,"phoneExt":17,"email":17},{"name":106,"role":68,"phone":17,"phoneExt":17,"email":17},"Christiane Sackbrook, MD",{"name":108,"role":68,"phone":17,"phoneExt":17,"email":17},"Anke Zbikowski, MD",{"name":110,"role":68,"phone":17,"phoneExt":17,"email":17},"Narmin Rasul, MD",{"facility":112,"status":48,"city":113,"state":113,"zip":114,"country":51,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"Department of Oncology, Linköping University Hospital","Linköping","58185",{"type":53,"coordinates":116},[117,118],15.62157,58.41086,{"lat":118,"lon":117},[121,123,124,126,128],{"name":31,"role":38,"phone":39,"phoneExt":17,"email":122},"gabriel.lindahl@regionostergotland.se",{"name":31,"role":65,"phone":17,"phoneExt":17,"email":17},{"name":125,"role":68,"phone":17,"phoneExt":17,"email":17},"Annika Holmquist, MD, PhD",{"name":127,"role":68,"phone":17,"phoneExt":17,"email":17},"Oscar Derke, MD",{"name":129,"role":68,"phone":17,"phoneExt":17,"email":17},"Tommy Leijon, MD",{"facility":131,"status":48,"city":132,"state":132,"zip":133,"country":51,"cosmosGeoPoint":134,"geoPoint":138,"contacts":139},"Department of Obstetrics and Gynaecology, Norrland University Hospital","Umeå","90719",{"type":53,"coordinates":135},[136,137],20.25972,63.82842,{"lat":137,"lon":136},[140,144,145,147],{"name":141,"role":38,"phone":142,"phoneExt":17,"email":143},"Ulrika Ottander, MD, PhD","+46907850000","Ulrika.Ottander@umu.se",{"name":141,"role":65,"phone":17,"phoneExt":17,"email":17},{"name":146,"role":68,"phone":17,"phoneExt":17,"email":17},"Charlotte Öfverman, MD, PhD",{"name":148,"role":68,"phone":17,"phoneExt":17,"email":17},"Pernilla Israelsson, MD, PhD",{"facility":150,"status":48,"city":151,"state":151,"zip":152,"country":51,"cosmosGeoPoint":153,"geoPoint":157,"contacts":158},"Department of Obstetrics and Gynecology, Värnamo Hospital","Värnamo","33152",{"type":53,"coordinates":154},[155,156],14.04001,57.18604,{"lat":156,"lon":155},[159,162],{"name":160,"role":38,"phone":61,"phoneExt":17,"email":161},"Shefqet Halili, MD","shefqet.halili@rjl.se",{"name":160,"role":65,"phone":17,"phoneExt":17,"email":17},{"facility":164,"status":48,"city":165,"state":165,"zip":166,"country":51,"cosmosGeoPoint":167,"geoPoint":171,"contacts":172},"Department of Obstetrics and Gynecology, Västervik Hospital","Västervik","593 81",{"type":53,"coordinates":168},[169,170],16.63733,57.7584,{"lat":170,"lon":169},[173,177,178],{"name":174,"role":38,"phone":175,"phoneExt":17,"email":176},"Anders Rosenmüller, MD","+4649086000","anders.rosenmuller@regionkalmar.se",{"name":174,"role":65,"phone":17,"phoneExt":17,"email":17},{"name":179,"role":68,"phone":17,"phoneExt":17,"email":17},"Helena Avenström, MD",{"facility":181,"status":182,"city":113,"state":183,"zip":114,"country":51,"cosmosGeoPoint":184,"geoPoint":186,"contacts":17},"Department of Obstetrics and Gynecology, University Hospital","ACTIVE_NOT_RECRUITING","Östergötland County",{"type":53,"coordinates":185},[117,118],{"lat":118,"lon":117},{"type":65,"investigatorFullName":188,"investigatorTitle":189,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"Preben Kjolhede, MD, professor","Professor, senior consultant",[191,194,196,198],{"name":192,"class":193},"Region Jönköping County","OTHER_GOV",{"name":195,"class":6},"Västervik Hospital",{"name":197,"class":193},"Vastra Gotaland Region",{"name":199,"class":193},"Region Västerbotten","100461124",false,"NCT05284552","Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer","The Effect of Tinzaparin on Biomarkers in FIGO Stage III-IV Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy - A Randomized Pilot Study","Inclusion Criteria:\n\n* The subject has given written consent to participate in the study.\n* Age 18 and above\n* Epithelial ovarian, fallopian tube or peritoneal cancer, or abdominal cancer where a biopsy indicates an origin from the ovary, fallopian tube or peritoneum.\n* Histology diagnosis of either high grade serous carcinoma, endometroid carcinoma or clear cell carcinoma.\n* FIGO stage III-IV disease.\n* Planned for platinum-based chemotherapy\n* Prior to start of NACT pregnancy should be ruled out by menstrual history or in unclear cases by a urine hCG test.\n* Women of childbearing potential should use a safe birth control method (combined hormonal contraception, progesterone only hormonal contraception, intra uterine device, bilateral tubal occlusion, vasectomized partner, sexual abstinence, male or female condom, diaphragm with spermicide).\n* WHO Performance Status 0-2\n* Weight 50-150 kg\n* CA-125-level ≥250 kIE\u002FL at diagnosis\n\nExclusion Criteria:\n\n* Concomitant treatment with heparins, low molecular weight heparins, warfarin or non-vitamin K antagonist oral anticoagulants. Platelet inhibitors are allowed.\n* Treatment with heparins, low molecular weight heparins or non-vitamin K antagonist oral anticoagulants within the last year.\n* Known or suspected allergies against any product included in the study\n* Ongoing pregnancy, independent of gestational age. Breastfeeding or planned pregnancy\n* EOC disclosed at Cesarean section\n* Abdominal surgery or other major surgery within the last year\n* Mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of study participation\n* Treatment or disease which, according to the investigator, can affect treatment or study results\n* Known brain metastasis\n* Participation or recent participation (within the last 30 days) in a clinical study with an investigational product\n* Ongoing treatment of thromboembolic disease.\n* Thromboembolic disease within the last year.\n* Hypersensitivity to the active substance (tinzaparin) or any of the excipients.\n* Serious hemorrhage or conditions predisposing to serious hemorrhage. Serious hemorrhage is defined as fulfilling any one of these three criteria:\n\n  1. occurs in a critical area or organ (e.g. intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, intra-uterine or intramuscular with compartment syndrome),\n  2. causes a fall in hemoglobin level of 20 g\u002FL (1.24 mmol\u002FL) or more, or\n  3. leads to transfusion of two or more units of whole blood or red blood cells.\n* Severe coagulation disorder.\n* Acute gastro duodenal ulcer.\n* Septic endocarditis.\n* Previous heparin-induced thrombocytopenia.\n* WHO Performance Status \\>2.\n* E-GFR \\\u003C30ml\u002Fmin (analyzed no more than 14 days before start of treatment with investigational product)\n* Platelets \\\u003C100 x10\\^9\u002FL (analyzed no more than 14 days before start of treatment with investigational product)\n* Treatment for other known malignancy within the last year (except basal cell carcinoma)","FEMALE","18 Years",{"count":209,"type":210},40,"ESTIMATED","INTERVENTIONAL",[213],"PHASE2","Background:\n\nPrevious findings have indicated antineoplastic properties of tinzaparin (Innohep®), a commonly used anti-coagulant. Earlier studies have mainly investigated the antineoplastic effects of tinzaparin in animal models and in human cell-lines. In this pilot study the aim is to examine the potential antitumoral effects of tinzaparin in vivo in women with epithelial ovarian cancer (EOC).\n\nStudy objectives:\n\nPrimary objective: The primary objective of the study is to evaluate the effects of tinzaparin on changes in levels of CA-125 in EOC patients who receive neoadjuvant chemotherapy (NACT).\n\nSecondary objectives: The secondary objective of the study is to explore the impact of tinzaparin on the dynamic of a spectrum of immunological and coagulation factors in EOC patients who receive NACT. Besides, the compliance of tinzaparin injections and adverse events caused by tinzaparin will be described.",[216],"Epithelial Ovarian Cancer",[218,219,220],"Tinzaparin","Neoadjuvant chemotherapy","FIGO stage III-IV","2026-05-06",{"date":223,"type":224},"2026-05-11","ACTUAL",{"date":226,"type":224},"2022-07-12",{"date":228,"type":210},"2027-12",{"name":5,"class":6},8]